KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Decrease in Short Interest

KALA BIO, Inc. (NASDAQ:KALA) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 5,100 shares, a drop of 15.0% from the March 31st total of 6,000 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 20,500 shares, the short-interest ratio is presently 0.2 days.

KALA BIO Stock Performance

KALA BIO stock opened at $6.90 on Wednesday. The stock’s 50-day moving average is $7.37 and its 200-day moving average is $7.13. The company has a market cap of $19.46 million, a price-to-earnings ratio of -0.38 and a beta of -1.85. The company has a debt-to-equity ratio of 5.10, a current ratio of 6.33 and a quick ratio of 6.33. KALA BIO has a 12 month low of $5.10 and a 12 month high of $19.35.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Friday, March 29th. The company reported ($3.18) earnings per share (EPS) for the quarter. Equities analysts anticipate that KALA BIO will post -11.28 earnings per share for the current year.

Wall Street Analyst Weigh In

KALA has been the topic of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a research note on Monday, April 1st. HC Wainwright cut their price objective on KALA BIO from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently raised its stake in KALA BIO stock. Knights of Columbus Asset Advisors LLC increased its stake in KALA BIO, Inc. (NASDAQ:KALA) by 100.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,834 shares of the company’s stock after buying an additional 2,417 shares during the quarter. Knights of Columbus Asset Advisors LLC owned about 0.18% of KALA BIO worth $34,000 as of its most recent filing with the SEC. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.